Codexis Stock Forecast, Price & News

Codexis (NASDAQ:CDXS) Frequently Asked Questions

Is Codexis a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Codexis in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Codexis stock.
View analyst ratings for Codexis or view top-rated stocks.

How has Codexis' stock been impacted by COVID-19?

Codexis' stock was trading at $10.12 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CDXS shares have increased by 117.7% and is now trading at $22.03.
View which stocks have been most impacted by COVID-19.

When is Codexis' next earnings date?

Codexis is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Codexis.

How were Codexis' earnings last quarter?

Codexis, Inc. (NASDAQ:CDXS) issued its quarterly earnings data on Thursday, November, 4th. The biotechnology company reported $0.03 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.09) by $0.12. The biotechnology company had revenue of $36.77 million for the quarter, compared to analyst estimates of $28.52 million. Codexis had a negative trailing twelve-month return on equity of 9.02% and a negative net margin of 14.82%. Codexis's quarterly revenue was up 100.0% compared to the same quarter last year. During the same period last year, the firm posted ($0.10) earnings per share.
View Codexis' earnings history.

What guidance has Codexis issued on next quarter's earnings?

Codexis issued an update on its FY 2021 earnings guidance on Thursday, December, 2nd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $98 million-$103 million, compared to the consensus revenue estimate of $101.77 million.

What price target have analysts set for CDXS?

5 brokers have issued 12 month price targets for Codexis' stock. Their forecasts range from $30.00 to $38.00. On average, they anticipate Codexis' stock price to reach $32.80 in the next twelve months. This suggests a possible upside of 48.9% from the stock's current price.
View analysts' price targets for Codexis or view top-rated stocks among Wall Street analysts.

Who are Codexis' key executives?

Codexis' management team includes the following people:

• John J. Nicols, President, Chief Executive Officer & Director (LinkedIn Profile)
• Karl A. Schoene, Senior Vice President-Development & Operations
• Ross Taylor, Chief Financial Officer & Senior Vice President
• Stefan Lutz, Senior Vice President-Research
• Asli Aras, Vice President-Corporate Development

What is John J. Nicols' approval rating as Codexis' CEO?

25 employees have rated Codexis CEO John J. Nicols on Glassdoor.com. John J. Nicols has an approval rating of 68% among Codexis' employees.

Who are some of Codexis' key competitors?

Some companies that are related to Codexis include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Exact Sciences (EXAS), Repligen (RGEN), United Therapeutics (UTHR), Novavax (NVAX), Neurocrine Biosciences (NBIX) and Arena Pharmaceuticals (ARNA).
View all of CDXS's competitors.

What other stocks do shareholders of Codexis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Codexis investors own include Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Micron Technology (MU), (CGC), Enphase Energy (ENPH), Intellia Therapeutics (NTLA), NVIDIA (NVDA), OPKO Health (OPK) and Antares Pharma (ATRS).

What is Codexis' stock symbol?

Codexis trades on the NASDAQ under the ticker symbol "CDXS."

Who are Codexis' major shareholders?

Codexis' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Exchange Traded Concepts LLC (0.10%) and Pendal Group Ltd (0.05%). Company insiders that own Codexis stock include Bernard J Kelley, Byron L Dorgan, Dennis P Wolf, John J Nicols, Patrick Y Yang and Thomas R Baruch.
View institutional ownership trends for Codexis.

Which major investors are selling Codexis stock?

CDXS stock was sold by a variety of institutional investors in the last quarter, including Exchange Traded Concepts LLC. Company insiders that have sold Codexis company stock in the last year include Bernard J Kelley, Byron L Dorgan, Dennis P Wolf, John J Nicols, and Patrick Y Yang.
View insider buying and selling activity for Codexis or view top insider-selling stocks.

Which major investors are buying Codexis stock?

CDXS stock was bought by a variety of institutional investors in the last quarter, including Pendal Group Ltd.
View insider buying and selling activity for Codexis or or view top insider-buying stocks.

How do I buy shares of Codexis?

Shares of CDXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Codexis' stock price today?

One share of CDXS stock can currently be purchased for approximately $22.03.

How much money does Codexis make?

Codexis has a market capitalization of $1.43 billion and generates $69.06 million in revenue each year. The biotechnology company earns $-24.01 million in net income (profit) each year or ($0.24) on an earnings per share basis.

How many employees does Codexis have?

Codexis employs 181 workers across the globe.

What is Codexis' official website?

The official website for Codexis is www.codexis.com.

Where are Codexis' headquarters?

Codexis is headquartered at 200 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063.

How can I contact Codexis?

Codexis' mailing address is 200 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063. The biotechnology company can be reached via phone at (650) 421-8100, via email at [email protected], or via fax at 650-421-8102.